The emerging role of cannabidiol (<scp>CBD</scp>) products; a survey exploring the public's use and perceptions of <scp>CBD</scp>

Bhamra, Sukvinder K.; Desai, Ankita; Imani-Berendjestanki, Parmis; Horgan, Maeve

doi:10.1002/ptr.7232

Cited by 36 publications

(43 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The survey in the US and Canada also found a positive association between cannabis use and CBD use. Similarly to other studies, our results confirm that a substantial proportion of those aware of CBD-based products did not have an opinion with regards to their harmfulness, and few perceived them as harmful [ 6 , 23 ].…”

Section: Discussionsupporting

confidence: 89%

“…Most CBD products can be purchased in specialized shops, pharmacies, and supermarkets (dried cannabis flowers cannot currently be purchased in pharmacies and supermarkets). However, this legal framework is probably confusing for most French citizens (as shown in a UK-based sample [ 6 ]). Indeed, cannabis use, including for therapeutic purposes, is criminalized in France.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cannabidiol use and perceptions in France: a national survey

et al. 2022

View full text Add to dashboard Cite

Background Cannabidiol (CBD), a safe, non-intoxicating cannabis component, is growing in popularity in Europe and worldwide. However, CBD EU regulation is blurry, and consequent labelling and product quality issues may have implications for public health. There is therefore a need to assess the prevalence and perceived harmfulness of CBD use in EU countries, as well as to characterise CBD users. We aimed to do so in the French population. Methods In December 2021, an online survey was conducted in a sample respecting the French adult population structure for key demographic variables. Sociodemographic, behavioural and CBD perception data were collected. Three separate regressions were performed to identify correlates of i) having heard of CBD, ii) using CBD, iii) perceived harmfulness of CBD. A hierarchical classification was also performed to identify profiles of CBD users. Results The study sample comprised 1969 adults, of whom 69.2% had heard of CBD and 10.1% used it. Less than half (46.8%) of the former considered it harmful. Having heard of CBD was associated with younger age, being born in France, tobacco use, and cannabis use. CBD use was associated with younger age, tobacco use, cannabis use, poor self-reported general health status, and positive perception of alternative medicines. Cluster analysis revealed four different CBD user profiles based on socio-demographics and behavioural characteristics. Conclusion Ten percent of the adults in this French study used CBD, and several user profiles emerged. Our results indirectly advocate clearer European CBD regulations to ensure safe and high-quality products.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 99%

Cannabidiol use and perceptions in France: a national survey

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The study has limitations that must be considered when interpreting these results. First, the survey used was created by the authors and was based on clinical expertise as well as other published studies (Corroon and Phillips, 2018 , Bhamra et al 2021 , Moltke et al, Schilling et al 2021 , Moeller-Bertram et al 2019 , Devitt 2019 ). Due to this novel survey design, there is concern for the validity of the survey.…”

Section: Discussionmentioning

confidence: 99%

“…The questionnaire was designed based on the outline of survey creation described by Passmore et al ( 2002 ). Additionally, previously published literature using surveys for CBD research were referenced (Corroon et al 2018 , Bhamra et al 2021 , Moltke et al, Schilling et al 2021 , Moeller-Bertram et al 2019 , Devitt 2019 ).…”

Section: Methodsmentioning

confidence: 99%

Cannabidiol as a treatment for arthritis and joint pain: an exploratory cross-sectional study

et al. 2022

View full text Add to dashboard Cite

Introduction An estimated 54 million Americans currently suffer from debilitating arthritis. Patients who have exhausted conservative measures can be subject to chronic pain and resort to symptomatic management with anti-inflammatories, acetaminophen, and opioids. Cannabidiol (CBD) is a non-psychoactive cannabinoid that has shown promise in preclinical studies to reduce inflammation and pain associated with arthritis. The purpose of this study was to explore patient perceived effects of cannabidiol on symptoms of arthritis. Methods A novel anonymous questionnaire was created to evaluate perceived efficacy of cannabidiol for the treatment of arthritis. A self-selected convenience sample (N=428) was recruited through online methods including social media accounts and newsletters (The Arthritis Foundation and Savvy Cooperative) between May 5, 2020, and November 5, 2020. Statistical analysis was performed to determine differences between types of arthritis and improvements in quality-of-life symptoms. Furthermore, a regression analysis was performed to identify variables associated with decreasing or discontinuing other medications. Results CBD use was associated with improvements in pain (83%), physical function (66%), and sleep quality (66%). Subgroup analysis by diagnosis type (osteoarthritis, rheumatoid, or other autoimmune arthritis) found improvements among groups for physical function (P=0.013), favoring the osteoarthritis group. The overall cohort reported a 44% reduction in pain after CBD use (P<0.001). The osteoarthritis group had a greater percentage reduction (P=0.020) and point reduction (P<0.001) in pain compared to rheumatoid arthritis and other autoimmune arthritis. The majority of respondents reported a reduction or cessation of other medications after CBD use (N=259, 60.5%): reductions in anti-inflammatories (N=129, 31.1%), acetaminophen (N=78, 18.2%), opioids (N=36, 8.6%) and discontinuation of anti-inflammatories (N=76, 17.8%), acetaminophen (N=76, 17.8%), and opioids (N=81, 18.9%). Conclusion Clinicians and patients should be aware of the various alternative therapeutic options available to treat their symptoms of arthritis, especially in light of the increased accessibility to cannabidiol products. The present study found associations between CBD use and improvements in patient’s arthritis symptoms and reductions in other medications. Future research should focus on exploring the benefits of CBD use in this patient population with clinical trials.

show abstract

“…Cannabis and cannabinoids research studies are attracting much interest in Phytotherapy Research, as highlighted by recent articles published in the Journal (see, e.g., Bhamra, Desai, Imani‐Berendjestanki, & Horgan, 2021; Corpetti et al, 2021; Kumar et al, 2021; Muscarà et al, 2021; Riera, Pacheco, Bagattini, & Martimbianco, 2022). Among these, Kumar and colleagues discussed the medicinal potential of the plant preparations and their legal status worldwide.…”

mentioning

confidence: 99%